There was also a bit of detail on VAST.
It was indicated that while Audeo Oncology would exclusively license all of the technology there was one family of patents that are currently licensed to another party. Audeo Oncology will pay Alchemia 5% of revenue received by Audeo Oncology (presumably from VAST). Audeo Oncology will have to employ four full time equivalent researchers to exploit the VAST platform and will need to spend $1.5 million per year on developing the technology.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable